Journal article
Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer


Research Areas
Currently no objects available

Publication Details
Author list: Mohammad Azam Ansari, Muthu Thiruvengadam, Zeba Farooqui, Govindaswamy Rajakumar, Qazi Mohammad Sajid Jamal, Mohammad A. Alzohairy, Ahmad Almatroudi, Mohammad N. Alomary, Ill-Min Chung, and Ebtesam Abdullah Al-Suhaimi
Publisher: Elsevier: 12 months
Publication year: 2021
Journal: Seminars in Cancer Biology
Journal name in source: Seminars in Cancer Biology
Volume number: 69
Issue number: February 2021
Start page: 109
End page: 128
Number of pages: 20
ISSN: 1044-579X
Web of Science ID: 000631703400008
PubMed ID: 31891780
Scopus ID: 85077385414
eISSN: 1096-3650


Breast cancer is one of the most prevalent and reoccurring cancers and the second most common reason of death in women. Despite advancements in therapeutic strategies for breast cancer, early tumor recurrence and metastasis in patients indicate resistance to chemotherapeutic medicines, such as paclitaxel due to the abnormal expression of ER and EGF2 in breast cancer cells. Therefore, the development of alternatives to paclitaxel is urgently needed to overcome challenges involving drug resistance. An increasing number of studies has revealed miRNAs as novel natural alternative substances that play a crucial role in regulating several physiological processes and have a close, adverse association with several diseases, including breast cancer. Due to the therapeutic potential of miRNA and paclitaxel in cancer research, the current review focuses on the differential roles of various miRNAs in breast cancer development and treatment. miRNA delivery to a specific target site, the development of paclitaxel and miRNA formulations, and nanotechnological strategies for the delivery of nanopaclitaxel in the management of breast cancer are discussed. These strategies involve improving the cellular uptake and bioavailability and reducing the toxicity of free paclitaxel to achieve accumulation tumor site. Furthermore, a molecular docking study was performed to ascertain the enhanced anticancer activity of the nanoformulation of ANG1005 and Abraxane. An in silico analysis revealed that ANG1005 and Abraxane nanoformulations have superior and significantly enhanced interactions with the proteins α-tubulin and Bcl-2. Therefore, ANG1005 and Abraxane may be more suitable in the therapeutic management of breast cancer than the existing free paclitaxel. miRNAs can revert abnormal gene expression to normalcy; since miRNAs serve as tumor suppressors. Therefore, restoration of particular miRNAs levels as a replacement therapy may be an effective endocrine potential strategy for treating ER positive/ negative breast cancers.


Projects
Currently no objects available

Keywords
Currently no objects available

Documents
Currently no objects available

Last updated on 2021-10-06 at 14:16